国产中文无码av每日更新在线观看, 亚洲天堂中文字幕一区二区三区免费, 国产口爆吞精在线观视频-黄色国产, 92福利-国内精品久久久久久99,亚洲成AV人A片不卡无码,浪潮AV无码专区,老熟女败火白浆,中文字幕日产av,色情日本免费看大片

400-885-9898
更新于 今天
智聯(lián)APPAPP
舉報

體外藥理學副總監(jiān)/總監(jiān)(J18004)

4-5萬·16薪
  • 上海浦東新區(qū)
  • 10年以上
  • 博士
  • 全職
  • 招1人

職位描述

免疫學藥理VITRO
崗位職責:
-Lead a small group to design, optimize, and validate of of novel therapeutic candidates.
-Utilize internal facilities or manage external CRO in supporting of preclinical PCC and IND enabling studies through clinical development
-Propose and lead new projects in both autoimmune and oncology fields
-Oversee project prioritization, resource allocation, and timelines to ensure the timely delivery of high-quality data
-Serves as the functional representative to work with teams from other disciplines
-Present research findings at internal and external project meetings in both Chinese and English
-Review research documents, including study reports, regulatory filings (e.g., IND), and scientific publications
-Lab and equipment management
任職要求:
-Ph.D. in Immunology, Cell Biology, Molecular Biology, Biochemistry, or a related discipline is required
-A 8+ years of job-related experience preferably in a biopharmaceutical R&D setting, with a strong focus on preclinical bioassay development is required
-PTL experience in supporting PCC and IND enabling studies is required.
-Proven records of in vitro cell based functional assay using various types of immune cells and tumor cells, and cell-based assay development is required, including but not limited to reporter assay, ELISA, BLI/SPR, flow cytometry, cell adhesion and migration, killing. T-cell/Treg/NK/basophil activation, T-cell cytotoxicity, cytokine profiling, ADCC, ADCP, CDC), GPCR signalling, epitope analysis.
-Experience in organoid culture, and mammalian tissue assay is preferred
-Excellent communication skills and problem-solving skills, with the ability to effectively collaborate in a fast-paced, cross-functional environment.
-Experience and knowledge in tumor immunology and Inflammatory diseases is a plus
-Strong publication and presentation record in relevant scientific fields is desired.
-Excellent written and communication in English

工作地點

浦東新區(qū)上海復星健康科技(集團)有限公司1號樓8樓

職位發(fā)布者

孫女士/招聘主管

昨日活躍
立即溝通
公司Logo上海復宏漢霖生物技術股份有限公司
復宏漢霖（2696.HK）是一家國際化的創(chuàng)新生物制藥公司，致力于為全球患者提供可負擔的高品質生物藥，產(chǎn)品覆蓋腫瘤、自身免疫疾病、眼科疾病等領域，已在中國上市5款產(chǎn)品，在國際上市1款產(chǎn)品，18項適應癥獲批，3個上市申請分別獲中國藥監(jiān)局、美國FDA和歐盟EMA受理。自2010年成立以來，復宏漢霖已建成一體化生物制藥平臺，高效及創(chuàng)新的自主核心能力貫穿研發(fā)、生產(chǎn)及商業(yè)運營全產(chǎn)業(yè)鏈。公司已建立完善高效的全球創(chuàng)新中心，按照國際藥品生產(chǎn)質量管理規(guī)范（GMP）標準進行生產(chǎn)和質量管控，不斷夯實一體化綜合生產(chǎn)平臺，其中，上海徐匯基地已獲得中國和歐盟GMP認證，松江基地（一）也已獲得中國GMP認證。復宏漢霖前瞻性布局了一個多元化、高質量的產(chǎn)品管線，涵蓋20多種創(chuàng)新單克隆抗體，并全面推進基于自有抗PD-1單抗H藥漢斯狀?的腫瘤免疫聯(lián)合療法。繼國內(nèi)首個生物類似藥漢利康?（利妥昔單抗）、中國首個自主研發(fā)的中歐雙批單抗藥物漢曲優(yōu)?（曲妥珠單抗，歐洲商品名：Zercepac?，澳大利亞商品名：Tuzucip?和Trastucip?）、漢達遠?（阿達木單抗）和漢貝泰?（貝伐珠單抗）相繼獲批上市，創(chuàng)新產(chǎn)品漢斯狀?（斯魯利單抗）已獲批用于治療微衛(wèi)星高度不穩(wěn)定（MSI-H）實體瘤、鱗狀非小細胞肺癌和廣泛期小細胞肺癌，成為全球首個獲批一線治療小細胞肺癌的抗PD-1單抗，其食管鱗狀細胞癌適應癥的上市注冊申請也正在審評中。公司亦同步就16個產(chǎn)品在全球范圍內(nèi)開展30多項臨床試驗。
公司主頁